Please ensure Javascript is enabled for purposes of website accessibility

Why Alkermes Shares Jumped for Joy

By Sean Williams - Apr 17, 2013 at 1:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Alkermes shares pop following the release of positive mid-stage trial data.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Alkermes (ALKS -2.33%), a diversified biopharmaceutical company, rose as much as 16% after the company announced positive clinical results for ALKS-5461 in a mid-stage trial to treat major depressive disorder, or MDD.

So what: The oral, non-addictive, opioid modulating drug was tested on 142 patients with MDD that had not responded to the current standard of treatment. In trials, the ALKS-5461 arm met its primary endpoint of changing the baseline in depressive symptoms over a four-week period as defined by the Hamilton Depression Rating Scale. The release also notes that the drug was well-tolerated. Alkermes plans to meet with the Food and Drug Administration soon in an attempt to advance ALKS-5461 into a development program.

Now what: I definitely believe that Alkermes shareholders have more than enough reason to turn those frowns upside down today! Rumblings on Wall Street are that, if approved, ALKS-5461 could have a market opportunity around $500 million. However, I'd forecast considerably more upside given the current one-size-fits-all nature of depression medications. As long as Alkermes can demonstrate non-dependence and a similar safety profile to existing depression medications, it could have a good shot at gaining approval since the results so far have spoken for themselves.

Craving more input? Start by adding Alkermes to your free and personalized watchlist so you can keep up on the latest news with the company.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alkermes plc Stock Quote
Alkermes plc
ALKS
$29.30 (-2.33%) $0.70

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.